Get the Stockscreener App
85.53
0.08%
-0.07
After Hours:
85.01
-0.52
-0.61%
Arrowhead Pharmaceuticals Inc stock is traded at $85.53, with a volume of 2.44M.
It is down -0.08% in the last 24 hours and up +8.42% over the past month.
Arrowhead Pharmaceuticals Inc is a commercial-stage pharmaceutical company. It is focused on the development of medicines for diseases associated with genetic abnormalities or protein overproduction. The company develops potential RNAi therapies designed to inhibit the expression of genes known to trigger diseases. Its portfolio includes potential drugs targeting Cardiometabolic, Neuromuscular, Pulmonary, Liver, and other diseases. The company also develops RNAi products and clinical candidates designed to target different cell types within the body.
See More
Previous Close:
$85.60
Open:
$85.77
24h Volume:
2.44M
Relative Volume:
1.12
Market Cap:
$12.05B
Revenue:
$622.01M
Net Income/Loss:
$-271.86M
P/E Ratio:
-39.81
EPS:
-2.1484
Net Cash Flow:
$-45.87M
1W Performance:
+19.37%
1M Performance:
+8.42%
6M Performance:
+27.83%
1Y Performance:
+443.39%
1-Day Range:
$85.21
$87.93
1-Week Range:
$72.62
$95.49
52-Week Range:
$15.01
$95.49
Arrowhead Pharmaceuticals Inc Stock (ARWR) Company Profile
Name
Arrowhead Pharmaceuticals Inc
Sector
Industry
Phone
626-696-4702
Address
177 E COLORADO BLVD, PASADENA, CA
Compare ARWR vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARWR
Arrowhead Pharmaceuticals Inc
|
85.53 | 12.06B | 622.01M | -271.86M | -45.87M | -2.1484 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Arrowhead Pharmaceuticals Inc Stock (ARWR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-21-26 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-05-24 | Initiated | Goldman | Neutral |
| Dec-04-23 | Initiated | BofA Securities | Buy |
| Sep-19-23 | Initiated | Citigroup | Neutral |
| Jul-21-23 | Initiated | TD Cowen | Outperform |
| May-12-23 | Downgrade | SVB Securities | Outperform → Market Perform |
| Apr-26-23 | Initiated | SMBC Nikko | Outperform |
| Apr-12-23 | Upgrade | SVB Securities | Market Perform → Outperform |
| Mar-21-23 | Initiated | Bernstein | Mkt Perform |
| Sep-09-22 | Initiated | Morgan Stanley | Equal-Weight |
| May-11-22 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jan-19-22 | Resumed | Goldman | Buy |
| Aug-06-21 | Reiterated | Chardan Capital Markets | Buy |
| Jun-04-21 | Resumed | Robert W. Baird | Neutral |
| Feb-05-21 | Reiterated | H.C. Wainwright | Buy |
| Dec-21-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Dec-16-20 | Initiated | UBS | Buy |
| Nov-19-20 | Initiated | Citigroup | Buy |
| May-13-20 | Initiated | RBC Capital Mkts | Outperform |
| May-08-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Apr-15-20 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Mar-24-20 | Upgrade | SVB Leerink | Underperform → Mkt Perform |
| Mar-17-20 | Initiated | Goldman | Neutral |
| Jan-21-20 | Initiated | SVB Leerink | Underperform |
| Dec-13-19 | Initiated | Oppenheimer | Perform |
| Nov-29-19 | Reiterated | Chardan Capital Markets | Buy |
| Nov-27-19 | Reiterated | B. Riley FBR | Buy |
| Nov-25-19 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Oct-24-19 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Oct-22-19 | Reiterated | Chardan Capital Markets | Buy |
| Oct-03-19 | Initiated | Robert W. Baird | Outperform |
| Sep-07-18 | Upgrade | B. Riley FBR | Neutral → Buy |
| Sep-06-18 | Reiterated | Chardan Capital Markets | Buy |
| Aug-08-18 | Reiterated | Cantor Fitzgerald | Overweight |
| Jul-02-18 | Reiterated | Chardan Capital Markets | Buy |
View All
Arrowhead Pharmaceuticals Inc Stock (ARWR) Latest News
BlackRock discloses 10.1% Arrowhead Pharmaceuticals (ARWR) stake in latest 13G/A - Stock Titan
Arrowhead Pharmaceuticals Advances Zodasiran Study for HoFH Trea - GuruFocus
Arrowhead Pharmaceuticals (ARWR) Completes Enrollment in YOSEMITE Trial - GuruFocus
H.C. Wainwright raises Arrowhead Pharma price target to $115 on trial data - Investing.com Canada
Arrowhead Pharmaceuticals Completes Enrollment in Global Phase 3 YOSEMITE Study of Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia - Arrowhead Pharmaceuticals, Inc.
Arrowhead's Rare Cholesterol Disease Study Reaches 70 Patients - Stock Titan
Arrowhead Pharmaceuticals Inc (ARWR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Arrowhead Pharmaceuticals, Inc. Revenue Breakdown – BX:HDP1 - TradingView
Arrowhead Pharmaceuticals, Inc. Revenue Breakdown – XETR:HDP1 - TradingView
Is Arrowhead Pharmaceuticals on the Cusp of a Major Breakout - Kavout | AI
Arrowhead Pharmaceuticals, Inc. (ARWR) Stock Forecasts - Yahoo! Finance Canada
The 'Best-Case Scenario' That Shot Arrowhead Stock Sky-High - Investor's Business Daily
Is Arrowhead Pharmaceuticals Stock A Smart Buy After Its Transition To A Commercial Company? - Trefis
ARWR Reiterated by Piper Sandler -- Price Target Raised to $126 - GuruFocus
H.C. Wainwright reiterates Arrowhead Pharma stock rating on trial data By Investing.com - Investing.com Canada
Arrowhead shares surge as Phase III plozasiran studies deliver positive pancreatitis data - The Pharma Letter
Arrowhead Pharmaceuticals (ARWR) Hits 52-Week High Following Pos - GuruFocus
Arrowhead Pharmaceuticals (ARWR) Reports Positive Phase 3 Trial Results - GuruFocus
Arrowhead (ARWR) Sees Significant Stock Surge - GuruFocus
ARWR Stock Clocks Best Day In Nearly 8 Months As Analyst Lifts Price Target On Plozasiran Data - TradingView
Arrowhead Pharmaceuticals, Inc. Stock 12‑Month Price Target Raised to $101.6, Implies 36% Upside - TradingView
ARWR Stock Climbs As EU Greenlights REDEMPLO And Analysts Boost Targets - timothysykes.com
Arrowhead rises on phase III hypertriglyceridemia readout - BioWorld News
ARWR Maintained by Chardan Capital -- Price Target Raised to $115 - GuruFocus
Arrowhead Pharmaceuticals Shares Rise After Phase 3 Trials of Plozasiran Meets Primary, Secondary Endpoints - Moomoo
Arrowhead Pharmaceuticals Inc Stock (ARWR) Closed Up by 19.04% on Jul 22: What Signal Does It Send? - TradingKey
ARWR Stock Climbs As EU REDEMPLO Win Fuels Bullish Targets - StocksToTrade
Why Arrowhead Pharmaceuticals Is Surging 24.4%: JP Morgan Maintains Overweight - AlphaStreet
Arrowhead Pharmaceuticals (NASDAQ:ARWR) shares rise 23% after Plozasiran Phase 3 data released - TechStock²
Arrowhead (ARWR) Soars to New High as Plozasiran Nears Expanded Commercialization - Yahoo Finance
ARWR Stock Climbs As REDEMPLO Win Fuels Bullish Targets - timothysykes.com
Arrowhead Drug Shows Strong Efficacy In Cutting Blood Fat - Benzinga
Plozasiran Phase III Results Expand Cardiometabolic Use - AllSci
ARWR Stock Climbs As EU Approval And Analyst Targets Heat Up - StocksToTrade
Arrowhead: Stock Up On SHTG DataNo Ceiling On Valuation Growth Potential (NASDAQ:ARWR) - Seeking Alpha
Arrowhead stock jumps on late-stage trial win (ARWR:NASDAQ) - Seeking Alpha
Arrowhead Pharmaceuticals (ARWR) Achieves Late-Stage Trial Succe - GuruFocus
H.C. Wainwright Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Maintains Target Price $100 - Moomoo
ARWR Stock Climbs As EU Greenlights REDEMPLO, Street Lifts Targets - StocksToTrade
Arrowhead hits ‘best-case scenario’ with latest results for fat-lowering drug - BioPharma Dive
Why is Arrowhead Pharmaceuticals stock surging today? - Investing.com
Look out Ionis, here comes Arrowhead with promising hypertriglyceridemia data - Fierce Pharma
Arrowhead (ARWR) Shares Surge Over 22% - GuruFocus
Arrowhead puts pressure on Ionis with positive data for triglyceride lowering drug - BioSpace
Arrowhead Pharmaceuticals Reports Topline Results from Phase 3 SHASTA-3 and SHASTA-4 Studies of Plozasiran in Patients with Severe Hypertriglyceridemia - BioSpace
Arrowhead Pharmaceuticals: Redemplo Meets High Expectations In SHTG Trials (NASDAQ:ARWR) - Seeking Alpha
Arrowhead Pharmaceuticals stock hits 52-week high at $87.93 By Investing.com - Investing.com South Africa
Why is Arrowhead Pharmaceuticals stock surging today? By Investing.com - Investing.com Canada
ARWR Jumps As REDEMPLO Win Fuels Bullish Targets - StocksToTrade
Arrowhead Pharmaceuticals stock hits 52-week high at $87.93 - Investing.com
ARWR Stock On Track To Hit Over 5-Year Highs – Retail Cheers Phase 3 Breakthrough As Arrowhead Targets Broader FDA Approval - Yahoo Finance
Arrowhead Pharmaceuticals Inc Stock (ARWR) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.97%
0.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):